lvermectin Safety in Small Children (360G-Wellcome-220218_Z_20_Z)
lvermectin is a very safe and beneficial drug which is used for the treatment of more than a dozen different neglected tropical diseases (NTDs), many of which are associated with important public health problems. Current label indications for ivermectin prevent use in small children weighing less than 15kg, due to limited safety data in this group. Many of the NTD treatment options for small children rely on compounds that are less safe and/or efficacious compared to oral ivermectin. Our proposal will establish the safety and pharmacokinetics of escalating doses of ivermectin to treat scabies infected children weighing less than 15kg. The safety assessment will provide crucial evidence on the use of ivermectin for numerous diseases in children weighing less than 15kg. The information from measuring drug concentrations in the patients will inform the optimal dosing of this drug in small children. Assessment of the efficacy of ivermectin, compared to permethrin cream, for the treatment of scabies in small children can provide an important alternative treatment for this widespread disease.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 510000 |
Applicant Surname | Kobylinski |
Approval Committee | Internal Decision Panel |
Award Date | 2020-09-30T00:00:00+00:00 |
Financial Year | 2019/20 |
Grant Programme: Title | Innovations Priority Project |
Internal ID | 220218/Z/20/Z |
Lead Applicant | Dr Kevin Kobylinski |
Partnership Value | 510000 |
Planned Dates: End Date | 2024-04-01T00:00:00+00:00 |
Planned Dates: Start Date | 2020-04-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South East |